Literature DB >> 26504766

Construction and Characterization of Recombinant HEK Cell Over Expressing α4 Integrin.

Shamsi Naderi Beni1, Shirin Kouhpayeh2, Zahra Hejazi1, Nahid Heidari Hafshejani1, Hossein Khanahmad1.   

Abstract

PURPOSE: Integrins are heterodimeric membrane proteins, which are exposed to post translational modifications in eukaryotic cells in contrast to prokaryotic cells. These modifications provide advantages for production of proper nanobody, mono and polyclonal antibody against this surface protein and also in aptamer selection process. Since the majority of diagnostic and therapeutic antibodies, target the surface epitopes, eukaryotic membrane proteins provide an appropriate model for further investigation on therapeutic agents.
METHODS: Escherichia coli strain top 10, was used as host for ITGA-4 expression vector encoding the human integrin α4. The plasmid was extracted and consequently, ITGA-4 vector was digested to make a linear plasmid. Human Embryonic Kidney-293 (HEK-293) cell transfected with linear plasmid and subsequently screened for stable ITGA-4 expressing Cells. Three separated clones were isolated twenty one days after transfection. Chromosomal DNA was extracted from ITGA-4-transfected cells. The presence of ITGA-4 gene in HEK-293 genome was confirmed by PCR. The expression level of ITGA-4 on HEK-293 cells was also analyzed by Flow cytometry.
RESULTS: Flow cytometric analysis showed that HEK-293 cells have no expression of integrin α4 on their surface while 95% of transfected HEK-293 cells with ITGA4, expressed different levels of integrin α4 on their surfaces which correlates well with genomic DNA PCR amplification results.
CONCLUSION: The results suggest that we have successfully constructed the integrin α4 expressing HEK293 cell, which will facilitate further research into the production of antibody, nanobody and aptamer against α4 integrin.

Entities:  

Keywords:  Aptamer; Integrin α4; Multiple Sclerosis; Natalizumab; VCAM-1

Year:  2015        PMID: 26504766      PMCID: PMC4616894          DOI: 10.15171/apb.2015.058

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  21 in total

1.  Development of DNA aptamers using Cell-SELEX.

Authors:  Kwame Sefah; Dihua Shangguan; Xiangling Xiong; Meghan B O'Donoghue; Weihong Tan
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

2.  Distinct roles of integrins alpha6 and alpha4 in homing of fetal liver hematopoietic stem and progenitor cells.

Authors:  Hong Qian; Elisabeth Georges-Labouesse; Alexander Nyström; Anna Domogatskaya; Karl Tryggvason; Sten Eirik W Jacobsen; Marja Ekblom
Journal:  Blood       Date:  2007-06-22       Impact factor: 22.113

3.  Defective blood vessel development and pericyte/pvSMC distribution in alpha 4 integrin-deficient mouse embryos.

Authors:  Alison Grazioli; Christina S Alves; Konstantinos Konstantopoulos; Joy T Yang
Journal:  Dev Biol       Date:  2006-03-10       Impact factor: 3.582

4.  Nanobodies and their potential applications.

Authors:  Gholamreza Hassanzadeh-Ghassabeh; Nick Devoogdt; Pieter De Pauw; Cécile Vincke; Serge Muyldermans
Journal:  Nanomedicine (Lond)       Date:  2013-06       Impact factor: 5.307

Review 5.  Aptamers: multifunctional molecules for biomedical research.

Authors:  Jayeeta Banerjee; Marit Nilsen-Hamilton
Journal:  J Mol Med (Berl)       Date:  2013-09-18       Impact factor: 4.599

Review 6.  Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease.

Authors:  Giorgos Bamias; David J Clark; Jesús Rivera-Nieves
Journal:  Curr Drug Targets       Date:  2013-11       Impact factor: 3.465

7.  Integrin evolution: insights from ascidian and teleost fish genomes.

Authors:  Mikko Huhtala; Jyrki Heino; Daniele Casciari; Alessandra de Luise; Mark S Johnson
Journal:  Matrix Biol       Date:  2005-04       Impact factor: 11.583

Review 8.  [Cell adhesion molecules in evaluation of Crohn's disease therapy].

Authors:  L B Lazebnik; O N Boldyreva; A I Parfenov; I E Trubitsyna; P L Shcherbakov; S G Khomeriki; O V Kniazev; V É Sagynbaeva
Journal:  Eksp Klin Gastroenterol       Date:  2013

Review 9.  Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?

Authors:  Richard J Davenport; James R Munday
Journal:  Drug Discov Today       Date:  2007-06-26       Impact factor: 7.851

10.  Anti-integrin therapy for multiple sclerosis.

Authors:  Eiji Kawamoto; Susumu Nakahashi; Takayuki Okamoto; Hiroshi Imai; Motomu Shimaoka
Journal:  Autoimmune Dis       Date:  2012-12-17
View more
  5 in total

1.  Generation of HBsAg DNA aptamer using modified cell-based SELEX strategy.

Authors:  Mina Mirian; Shirin Kouhpayeh; Laleh Shariati; Maryam Boshtam; Ilnaz Rahimmanesh; Leila Darzi; Razieh Taghizadeh; Ali Jahanian-Najafabadi; Hossein Khanahmad
Journal:  Mol Biol Rep       Date:  2021-01-05       Impact factor: 2.316

2.  The silencing effect of miR-30a on ITGA4 gene expression in vitro: an approach for gene therapy.

Authors:  Leila Darzi; Maryam Boshtam; Laleh Shariati; Shirin Kouhpayeh; Azam Gheibi; Mina Mirian; Ilnaz Rahimmanesh; Hossein Khanahmad; Mohammad Amin Tabatabaiefar
Journal:  Res Pharm Sci       Date:  2017-12

3.  Construction and characterization of human embryonic kidney-(HEK)-293T cell overexpressing truncated α4 integrin.

Authors:  Azam Fatahi; Ilnaz Rahimmanesh; Mina Mirian; Fattah Rohani; Maryam Boshtam; Azam Gheibi; Laleh Shariati; Hossein Khanahmad; Shirin Kouhpayeh
Journal:  Res Pharm Sci       Date:  2018-08

4.  Selection and characterization of single-stranded DNA aptamers against interleukin-5.

Authors:  Mina Jamalvandi; Hossein Khanahmad; Shiva Irani; Sayad Bastaminezhad
Journal:  Res Pharm Sci       Date:  2019-12-11

5.  Display of human and rabbit monocyte chemoattractant protein-1 on human embryonic kidney 293T cell surface.

Authors:  Maryam Boshtam; Seddigheh Asgary; Ilnaz Rahimmanesh; Shirin Kouhpayeh; Jamal Naderi; Zahra Hejazi; Hoda Mohammad-Dezashibi; Ina Laura Pieper; Hossein Khanahmad
Journal:  Res Pharm Sci       Date:  2018-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.